| EBV-positive diffuse large B-cell lymphoma of the elderly CY Ok, TG Papathomas, LJ Medeiros, KH Young Blood, The Journal of the American Society of Hematology 122 (3), 328-340, 2013 | 255 | 2013 |
| Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries CY Ok, L Li, ZY Xu-Monette, C Visco, A Tzankov, GC Manyam, ... Clinical Cancer Research 20 (9), 2338-2349, 2014 | 153 | 2014 |
| EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management CY Ok, L Li, KH Young Experimental & Molecular Medicine 47 (1), e132-e132, 2015 | 148 | 2015 |
| Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases CY Ok, KP Patel, G Garcia-Manero, MJ Routbort, B Fu, G Tang, ... Leukemia research 39 (3), 348-354, 2015 | 144 | 2015 |
| Checkpoint inhibitors in hematological malignancies CY Ok, KH Young Journal of hematology & oncology 10, 1-16, 2017 | 136 | 2017 |
| TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases CY Ok, KP Patel, G Garcia-Manero, MJ Routbort, J Peng, G Tang, ... Journal of hematology & oncology 8, 1-8, 2015 | 129 | 2015 |
| DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk disease AE Quesada, MJ Routbort, CD DiNardo, CE Bueso‐Ramos, ... American journal of hematology 94 (7), 757-766, 2019 | 105 | 2019 |
| Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib P Jain, R Kanagal‐Shamanna, S Zhang, M Ahmed, A Ghorab, L Zhang, ... British journal of haematology 183 (4), 578-587, 2018 | 98 | 2018 |
| Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms V Nardi, KM Winkfield, CY Ok, A Niemierko, MJ Kluk, EC Attar, ... Journal of clinical oncology 30 (19), 2340, 2012 | 97 | 2012 |
| Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms CY Ok, RR Singh, F Vega The American journal of pathology 180 (1), 2-11, 2012 | 89 | 2012 |
| Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma CY Ok, J Chen, ZY Xu-Monette, A Tzankov, GC Manyam, L Li, C Visco, ... Clinical cancer research 20 (19), 5113-5123, 2014 | 78 | 2014 |
| Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)‐outcomes and mutation profile from venetoclax resistant MCL patients S Zhao, R Kanagal‐Shamanna, L Navsaria, CY Ok, S Zhang, K Nomie, ... American journal of hematology 95 (6), 623-629, 2020 | 64 | 2020 |
| Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia CY Ok, S Loghavi, D Sui, P Wei, R Kanagal-Shamanna, CC Yin, Z Zuo, ... Haematologica 104 (2), 305, 2019 | 64 | 2019 |
| Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma Y Xia, ZY Xu-Monette, A Tzankov, X Li, GC Manyam, V Murty, G Bhagat, ... Leukemia 31 (3), 625-636, 2017 | 60 | 2017 |
| Clinical and prognostic significance of 3q26. 2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors W Wang, JE Cortes, P Lin, MW Beaty, D Ai, HM Amin, TJ McDonnell, ... Blood, The Journal of the American Society of Hematology 126 (14), 1699-1706, 2015 | 56 | 2015 |
| Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia CY Ok, RP Hasserjian, PS Fox, F Stingo, Z Zuo, KH Young, K Patel, ... Leukemia 28 (1), 185-189, 2014 | 53 | 2014 |
| Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma P Jain, S Zhao, HJ Lee, HA Hill, CY Ok, R Kanagal-Shamanna, ... Journal of Clinical Oncology 40 (2), 202-212, 2022 | 52 | 2022 |
| Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL P Jain, S Zhang, R Kanagal-Shamanna, CY Ok, K Nomie, GN Gonzalez, ... Blood Advances 4 (6), 1038-1050, 2020 | 51 | 2020 |
| High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome AHG Cleven, V Nardi, CY Ok, M Goswami, P Dal Cin, Z Zheng, AJ Iafrate, ... Modern Pathology 28 (4), 552-563, 2015 | 51 | 2015 |
| High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma CY Ok, LJ Medeiros, B Thakral, G Tang, N Jain, E Jabbour, SA Pierce, ... Modern Pathology 32 (1), 48-58, 2019 | 50 | 2019 |
Mark Routbort, MD, PhDProfessor, UT MD Anderson Cancer CenterVerified email at mdanderson.org
